| Document Date: 2008-09-18 00:03:20
Open Document File Size: 22,91 KBShare Result on Facebook
City Palo Alto / Tokyo / DEERFIELD / / Company CV Therapeutics Inc. / CV Therapeutics Conference Call Company / Astellas Pharma Inc. / Astellas Pharma US Inc. / A2A / / Continent North America / / Country United States / / Currency USD / / Event FDA Phase / Conference Call / Business Partnership / / IndustryTerm telephone replays / radionuclide myocardial perfusion imaging / treatment of cardiovascular diseases / pharmaceutical / biopharmaceutical / chemical entity / pharmaceutical products / / MedicalCondition ventricular tachycardia / headache / sinus node dysfunction / nausea / heart disease / nonfatal myocardial infarction / cardiovascular diseases / hypotension / flushing / dyspnea / shortness of breath / AV block / chronic angina / serious hypotension / coronary artery disease / fatal cardiac arrest / dizziness / cerebrovascular insufficiency / / Organization U.S. Food and Drug Administration / FDA / / Person Louis G. Lange / Yoshihiko Hatanaka / / / Position chairman and chief executive officer / global category leader / clear market leader / president and chief executive officer / / Product Adenoscan / Ranexa / Adenosine / Lexiscan / Lexiscan(TM) (regadenoson) Injection / Ranexa(R) / pharmacologic / Use / / ProvinceOrState Illinois / California / / Technology AV / anti- infectives / drug development / / URL http /
SocialTag |
CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM) (regadenoson) Injection -First A2A Adenosine Receptor Agonist Approved for Use as Pharmacologic Stress Agent in Myocardial Perfusion ImagingPALO ALTO, C